It would be hard to argue that that there is a dearth of artificial intelligence platforms trying to get into the healthcare game. But it isn't just developers deciding where the industry is heading; it's also up to the healthcare players holding the purse strings. "Investors get a different view into technology than a lot of folks, and the decisions they make about where to put capital have big implications for what kind of technology, medicines, and products get developed," Meg Tirrell, a reporter at CNBC and a moderator for this week's AI World Medical Innovation Forum in Boston, said during an investor-focused panel discussion. At the conference, where key investors in the field came together to talk about where they see the future of AI, most agreed that, in general, implementation of AI is in its very early stages and somewhat burdened by hype. "I just went to HIMSS' conference and there were about 5,000 vendors, and almost all of them said they do AI, machine learning, patient engagement, and blockchain. But when you talk to them, few of them are using AI; most of them are algorithmic," Dr. Joe Cunningham, managing director at Sante Ventures, said during the session.